On the other hand, EGCG could inactivate Notch3/DLL3 signaling targeting SOX2OT variant 7 to reduce the stemness of OS cells and then abated drug-resistance of osteosarcoma cells. The gene discussed is NOTCH3; the disease is osteosarcoma.